Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Dany, Habr"'
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 115-129 (2023)
Abstract Introduction There has been a growing recognition on the importance of diversity in clinical trials. Existing research has highlighted a significant demographic imbalance. Amidst this renewed focus on diversity, it is crucial to acknowledge
Externí odkaz:
https://doaj.org/article/4a01c1547a3942f3b81f3272149ca898
Publikováno v:
Oncology and Therapy, Vol 11, Iss 1, Pp 15-24 (2023)
Plain Language Summary Pharmaceutical companies need to regularly communicate to patients all essential information about their medicines, especially data from the research studies that were conducted to evaluate the medicine’s benefits and risks.
Externí odkaz:
https://doaj.org/article/aa52a1b268d64def84624d6c199b9509
Publikováno v:
Oncology and Therapy, Vol 11, Iss 1, Pp 25-25 (2023)
Externí odkaz:
https://doaj.org/article/05246b16e7784174ad63744586d05363
Autor:
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analy
Externí odkaz:
https://doaj.org/article/418f46ca455548afb6402a31a5392284
Autor:
Dany Habr, Massimo Corsaro
Publikováno v:
Hematological oncologyREFERENCES. 40(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d7e7415e7b0c7d88de21ffdac2c96d
https://pubmed.ncbi.nlm.nih.gov/35391496
https://pubmed.ncbi.nlm.nih.gov/35391496
Autor:
Roxanne Ferdinand, Dany Habr
Publikováno v:
CancerReferences. 127(18)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85b12b94a7a6ab812b4be4b8d732fc2b
https://pubmed.ncbi.nlm.nih.gov/33904590
https://pubmed.ncbi.nlm.nih.gov/33904590
Autor:
Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Ali El-Ali, Dany Habr, Nicolas Martin, John B. Porter
Publikováno v:
Haematologica, Vol 98, Iss 7 (2013)
Reports are emerging of hematologic responses associated with iron chelation therapy; however, studies are limited in aplastic anemia patients. Deferasirox reduced iron overload in aplastic anemia patients enrolled in the EPIC (Evaluation of Patients
Externí odkaz:
https://doaj.org/article/be2d1486312041b2b09bae7c25444350
Autor:
Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Michael Stadler, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rose
Publikováno v:
Haematologica, Vol 97, Iss 9 (2012)
Background Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on these reductions/impr
Externí odkaz:
https://doaj.org/article/1b12aa5d995d45849a448b8e1f124671
Autor:
Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Publikováno v:
Haematologica, Vol 97, Iss 6 (2012)
Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important.Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing car
Externí odkaz:
https://doaj.org/article/8200d58999654e75addf9a56cafbe10d
Autor:
John Porter, Donald K. Bowden, Marina Economou, Jacques Troncy, Arnold Ganser, Dany Habr, Nicolas Martin, Adam Gater, Diana Rofail, Linda Abetz-Webb, Helen Lau, Maria Domenica Cappellini
Publikováno v:
Anemia, Vol 2012 (2012)
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adheren
Externí odkaz:
https://doaj.org/article/dc0eaa16090e46b9adb84445dd17e8bb